The effects of shortened dexamethasone administration on remission rate and potential complications during remission induction treatment for pediatric acute lymphoblastic leukemia |
Lee, Jae Wook
(Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Lee, Kwang Hee (Department of Pediatrics, College of Medicine, The Catholic University of Korea) Kwon, Young Joo (Department of Pediatrics, College of Medicine, The Catholic University of Korea) Lee, Dae Hyoung (Department of Pediatrics, College of Medicine, Hallym University) Chung, Nak Gyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea) Jeong, Dae Chul (Department of Pediatrics, College of Medicine, The Catholic University of Korea) Cho, Bin (Department of Pediatrics, College of Medicine, The Catholic University of Korea) Kim, Hack Ki (Department of Pediatrics, College of Medicine, The Catholic University of Korea) |
1 | Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998;339:605-15 DOI ScienceOn |
2 | Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-78 DOI ScienceOn |
3 | Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Infectious toxicity of dexamethasone during ALL remission-induction chemotherapy: report of two cases and literature review. Pediatr Hematol Oncol 2004;21:27-35 DOI ScienceOn |
4 | Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003;101: 3809-17 DOI ScienceOn |
5 | Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997;80:1717-26 DOI ScienceOn |
6 | Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001;113:103-14 DOI ScienceOn |
7 | Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;14:2223-33 |
8 | Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000;88:1964-9 DOI ScienceOn |
9 | Belgaumi AF, Al-Bakrah M, Al-Mahr M, Al-Jefri A, Al- Musa A, Saleh M, et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer 2003;97:2898-903 DOI ScienceOn |
10 | Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 2000;18:3262-72 DOI |
11 | Jones B, Freeman AI, Shuster JJ, Jacquillat C, Weil M, Pochedly C, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991;19:269-75 DOI ScienceOn |
12 | Yetgin S, Tuncer MA, Cetin M, Gumruk F, Yenicesu I, Tunc B, et al. Benefit of high-dose methlyprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up. Leukemia 2003;17:328-33 DOI ScienceOn |
13 | Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y, et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediaterisk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 Protocol. J Clin Oncol 2005;23:6489-98 DOI ScienceOn |
14 | Ito C, Evans WE, McNinch L, Coustan-Smith E, Mahmoud H, Pui CH, et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 1996;14:2370-6 DOI |
15 | Chung NG, Lee SJ, Kim SY, Jang PS, Cho B, Jeong DC, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. Korean J Pediatr Hematol-Oncol 2003;10:189-97 |
16 | Waber DP, Carpentieri SC, Klar N, Silverman LB, Schwenn M, Hurwitz CA, et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol 2000;22:206-13 DOI ScienceOn |
17 | Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000;96:24-33 |
18 | Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-8 DOI ScienceOn |
19 | Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33 |
20 | Schwartz CL, Thompson EB, Gelber RD, Young ML, Chilton D, Cohen HJ, et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol 2001;19:1040-6 DOI |
21 | Estlin EJ, Ronghe M, Burke GA, Yule SM. The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukemia. Br J Haematol 2000;110:780-90 DOI ScienceOn |
22 | Pui C-H. Childhood leukemias. N Engl J Med 1995;332: 1618-30 DOI ScienceOn |